Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026.
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?
Where Today's News Shapes Tomorrow
